Status:
UNKNOWN
Efficacy of Intravenous Gamma Globulin on Guillain-Barre Syndrome
Lead Sponsor:
Ning Wang, MD., PhD.
Conditions:
Guillain-barre Syndrome
Eligibility:
All Genders
18+ years
Brief Summary
Guillain-barre syndrome (GBS) is an acute immune-mediated polyneuropathy. Intravenous Gamma globulin is an effective therapy.Although high doses of gamma globulin are clinically effective, the patient...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Meet the Brighton Guillain-Barre Syndrome diagnosis criteria in 2014;
- Age ≥18;
- Patients with AIDP, AMAN and AMSAN;
- 5\. IVIG was treated within 2 weeks of onset; 6. GBS disability scale\>2; 6. Cooperate with patients who were followed up for 180 days and sign the informed consent;
- Exclusion criteria:
- Age \<18;
- Pregnant or nursing women;
- Patients with Chronic inflammatory demyelinating multiple peripheral neuropathy;
- Combined with other types of immune system diseases;
- Accept drugs that affect the function of the immune system within 5 or 3 months;
- Concomitant neoplastic diseases.
- The patient or guardian refused to sign the informed consent.
Exclusion
Key Trial Info
Start Date :
April 27 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 21 2025
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04303962
Start Date
April 27 2020
End Date
January 21 2025
Last Update
January 19 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Neurology,First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China, 350005